Education 1989 – 1994 Würzburg Medical School, Germany; 1996: Medical thesis
Professional Experience 1996 – 2002 Neurologist at Würzburg Medical School 2002 – 2004 Post Doc at the Institute of Human Genetics, Tübingen 2004 Habilitation at the Centre of Neurology, Tübingen 2004 – 2006 Senior Resident at the Centre of Neurology, Tübingen 2006 – 2016 Senior Physician at the Centre of Neurology, Tübingen Since 2008 PI of the TREND study (Tübinger evaluation of Risk factors for Early detection of NeuroDegeneration; https://www.trend-studie.de/) Since 2010 Member of the Scientific Advisory Board of the German Parkinson’s Disease Association (dPV) Since 2011 Board Member of the German Parkinson Society (DPG) Since 2015 Member of the Parkinson’s UK Research Strategy Board Until 2015 Head of the working group Clinical Neurodegeneration, Kiel Since 2016 Member of the International Executive Committee of the Movement Disorder Society (MDS) Since 2016 Chair and Director of the Department of Neurology in Kiel, Christian-Albrechts-University, Germany Since 2019 Member of the EAN Scientific Panel Movement disorders Since 2019 Chair of the commission of Movement Disorders of the German Society of Neurology Since 2020 Member of the “Fachbeirat” Deutsche Hirnstiftung e.V.
Besides training in Neurology Prof. Berg spent two years in a Department of Genetics. Moreover, she and elaborated a research focus in biomarker identification, design and conduction of cohort studies as well clinical studies with a focus on neurodegenerative diseases.
Early and differential diagnosis of neurodegenerative disorders, particularly the detection and validation of risk and biomarkers for diagnosis, progression, subtype identification and response to therapy in Parkinson’s disease. Prospective longitudinal cohort studies. Clinical studies including conservative approaches.
Maetzler W, Liepelt I, Berg D. Progression of Parkinson’s disease in the clinical phase: potential markers. Lancet Neurol 2009;8:1158-71.
Berg D, et al. Enlarged Substantia Nigra Hyperechogenicity and Risk for Parkin- son Disease. A 37-Month 3-Center Study of 1847 Older Persons. Arch Neurol 2011;68:932-7.
Berg D, …Deuschl G. MDS research criteria for prodromal Parkinson’s disease. Mov Disord 2015;30:1600-11.
Postuma RB, Berg D, …Stern M. The new definition and diagnostic criteria of Parkinson’s disease. Lancet Neurol 2016;15:546-8.
Del Din S, …Berg D, Rochester L, Maetzler W. Gait analysis with wearables pre- dicts conversion to Parkinson’s disease. Ann Neurol 2019;86:357-367
D. Berg is active in several national and international consortia, chaired among others the task force for the redefinition of Parkinson’s disease of the international Movement Disorders Society, is Board Member of the German Parkinson Society (DPG), which she chaired shared for several years, member of the Parkinson’s UK Research Strategy Board etc. She initiated several large prospective cohort studies and serves at different editorial boards.